To better evaluate translational potential, future studies should explore the development of an AAV expressing human DNase I and assess its efficacy in a humanized model, such as a human liver chimeric mouse, to more accurately reflect clinical relevance for the treatment of anti-MPO GN. Here, DNASE1 is linked to ganglioneuroma.